1062 GI-102, a novel CD80-IgG4-IL2v3 fusion protein driving lymphocyte expansion and anti-cancer pot...
1062 GI-102, a novel CD80-IgG4-IL2v3 fusion protein driving lymphocyte expansion and anti-cancer potential through regulation of immune cells in the tumor microenvironment
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundInterleukin-2 (IL-2) is a pleiotropic cytokine that plays pivotal roles in the immune response. It induces the proliferation of T cells and NK cells and demonstrates therapeutic anti-tumor activity. CD80 expressed on antigen-presenting cells provides co-stimulatory signals for T cell activation and immune responses via CD28 binding. Conve...
Alternative Titles
Full title
1062 GI-102, a novel CD80-IgG4-IL2v3 fusion protein driving lymphocyte expansion and anti-cancer potential through regulation of immune cells in the tumor microenvironment
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_b846b4f70dc544a2a55340674724ca1b
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b846b4f70dc544a2a55340674724ca1b
Other Identifiers
E-ISSN
2051-1426
DOI
10.1136/jitc-2023-SITC2023.1062
